Bevacizumab, a monoclonal antibody that targets VEGF, improves responses to chemotherapy and progression-free survival, but not overall survival, in patients with advanced gastric cancer.5, 6 In oesophagogastric cancer, a complete surgical resection (R0 resection) is an important predictor of long-term survival.7 This evidence concerns the gene VEGFA and gastric cancer.